Hepatic effects of GLP-1 mimetics in diabetic milieu: A mechanistic review of involved pathways
[ X ]
Tarih
2025
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier Science Inc
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Patients with diabetic are at a higher risk of developing hepatic disorders compared to non-diabetic individuals. This increased risk can be attributed to the diabetic environment, which triggers and exacerbates harmful pathways involved in both diabetic complications and hepatic disorders. Therefore, it is important to consider the use of antidiabetic agents that offer benefits beyond glycemic control and have positive effects on liver tissues. Glucagon-like peptide-1 (GLP-1) mimetics are a novel class of antidiabetic medications known for their potent blood sugar-lowering effects. Emerging evidence suggests that these drugs also have favorable effects on the liver. However, the precise effects and underlying mechanisms are not yet fully understood. In this review, we aim to provide a mechanistic perspective on the liver benefits of GLP-1 mimetics and outline the mediating mechanisms involved.
Açıklama
Anahtar Kelimeler
Keywords, Diabetes mellitus, GLP-1, Oxidative stress, Inflammation, Liver, Hepatic disorder, NAFLD
Kaynak
Journal of Diabetes and Its Complications
WoS Q Değeri
N/A
Scopus Q Değeri
Q2
Cilt
39
Sayı
1
